Skip to main content

Advertisement

Table 3 Treatment line progression, overall and by histologic categories

From: Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

  Histologic categories
All patients Leiomyo-sarcomas Undifferentiated pleomorphic Sarcoma Liposarcomas Vascular sarcomas Fibroblastic/myofibroblastic sarcomas Nerve sheath sarcomas Rhabdomyo-sarcomas Synovial sarcomas Others/NOS
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
All patients 4274 922 652 554 357 227 106 98 49 1309
Receiving first-line systemica treatment 1227 (28.7) 341 (37.0) 158 (24.2) 140 (25.3) 130 (36.4) 58 (25.6) 24 (22.6) 28 (28.6) 21 (42.9) 327 (25.0)
Duration, mean (SD) 4.1 (4.1) 4.1 (4.2) 4.4 (5.7) 4.3 (4.7) 4.4 (3.4) 4.2 (3.8) 3.3 (2.5) 4.5 (2.9) 3.9 (3.3) 3.8 (3.2)
Median 3.0 3.1 2.6 3.0 3.5 3.6 3.1 3.7 3.0 2.8
Receiving second-line systemica treatment 476 (11.1) 148 (16.1) 64 (9.8) 45 (8.1) 60 (16.8) 19 (8.4) 15 (15.3) 109 (8.3)
Duration, mean (SD) 4.6 (5.3) 4.5 (4.0) 5.1 (8.6) 5.5 (5.4) 4.6 (5.2) 4.7 (3.6) 3.2 (2.2) 4.3 (4.7)
Median 3.0 3.3 2.9 4.0 3.4 4.8 2.6 2.9
Receiving third-line systemica treatment 189 (4.4) 66 (7.2) 24 (3.7) 15 (2.7) 21 (5.9) 46 (3.5)
Duration, mean (SD) 4.0 (3.4) 4.6 (3.6) 3.3 (3.8) 2.8 (2.2) 5.1 (3.6) 3.4 (2.8)
Median 3.0 3.7 2.3 2.1 5.1 2.6
  1. Oral chemotherapy was not covered by Medicare until 2007
  2. SD standard deviation
  3. aSystemic therapy includes chemotherapy, biologic therapy, or targeted therapy